Veliparib

From Infogalactic: the planetary knowledge core
Jump to: navigation, search

Lua error in package.lua at line 80: module 'strict' not found.

Veliparib
File:Veliparib skeletal.svg
Systematic (IUPAC) name
2-((R)-2-Methylpyrrolidin-2-yl)-1H-benzimidazole-4-carboxamide
Clinical data
Legal status
  • experimental
Identifiers
ATC code none
PubChem CID: 11960529
IUPHAR/BPS 7417
DrugBank DB07232 N
ChemSpider 10134775 N
UNII 01O4K0631N YesY
ChEMBL CHEMBL506871 N
Chemical data
Formula C13H16N4O
Molecular mass 244.29 g/mol
  • NC(=O)c1cccc(n2)c1nc2C3(C)NCCC3
  • InChI=1S/C13H16N4O/c1-13(6-3-7-15-13)12-16-9-5-2-4-8(11(14)18)10(9)17-12/h2,4-5,15H,3,6-7H2,1H3,(H2,14,18)(H,16,17)/t13-/m1/s1 N
  • Key:JNAHVYVRKWKWKQ-CYBMUJFWSA-N N
 NYesY (what is this?)  (verify)

Veliparib (ABT-888)[1] is a potential anti-cancer drug acting as a PARP inhibitor. It kills cancer cells by blocking a protein called PARP, thereby preventing the repair of DNA or genetic damage in cancer cells and possibly making them more susceptible to anticancer treatments. Veliparib may make whole brain radiation treatment work more effectively against brain metastases from NSCLC.

It inhibits both PARP1 and PARP2.[2][3]

Clinical trials

Numerous phase I clinical trials are in progress.[4]

A phase I/II clinical trial for use with/out doxorubicin (for Metastatic or Unresectable Solid Tumors or Non-Hodgkin Lymphoma) started in 2008 and is due to complete in 2010.[5] Results (inc MTD) with topotecan.[6]

A phase II clinical trial for metastatic melanoma has started recruiting.[7] Due to end Dec 2011.

A phase II clinical trial for metastatic breast cancer has started recruiting.[8] Due to end Nov 2011.

A phase II clinical trial for add-on to Radiation Therapy for Patients with Brain Metastases from Non-Small Cell Lung Cancer.

It was included in the I-SPY2 breast cancer trial,[9] and there are encouraging data from that study [10]

A phase I clinical trial for prostate cancer in men who carry the BRCA mutation is underway and is now recruiting (as of May 2013).[11]

References

<templatestyles src="Reflist/styles.css" />

Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />

External links

http://kdwn.com/2013/12/16/new-drug-study-method-show-breast-cancer-promise/


<templatestyles src="Asbox/styles.css"></templatestyles>

Stub icon

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.
  1. ↑ "ABT-888, an Orally Active Poly(ADP-Ribose) Polymerase Inhibitor that Potentiates DNA-Damaging Agents in Preclinical Tumor Models" May 2007
  2. ↑ http://www.cancer.gov/drugdictionary/?CdrID=496464
  3. ↑ "ABT-888, an Orally Active Poly(ADP-Ribose) Polymerase Inhibitor that Potentiates DNA-Damaging Agents in Preclinical Tumor Models", 2007
  4. ↑ http://clinicaltrialsfeeds.org/clinical-trials/results/term=Drug:+ABT-888
  5. ↑ "ABT-888 and Cyclophosphamide With Versus Without Doxorubicin in Treating Patients With Metastatic or Unresectable Solid Tumors or Non-Hodgkin Lymphoma"
  6. ↑ Lua error in package.lua at line 80: module 'strict' not found.
  7. ↑ "A Study Evaluating Efficacy of ABT-888 in Combination With Temozolomide in Metastatic Melanoma"
  8. ↑ "ABT-888 and Temozolomide for Metastatic Breast Cancer"
  9. ↑ "Breast cancer study aims to speed drugs, cooperation", March 2010
  10. ↑ http://www.centerwatch.com/news-online/article/5737/new-presurgery-combination-therapy-for-triple-negative-breast-cancer
  11. ↑ "Veliparib in Treating Patients With Malignant Solid Tumors That Did Not Respond to Previous Therapy. Clinical Trial NCT00892736"
Retrieved from "https://infogalactic.com/w/index.php?title=Veliparib&oldid=2271439"